SUNNYVALE, Calif., July 14, 2016 /PRNewswire/ -- Accuray
Incorporated (NASDAQ: ARAY) announced today that its
CyberKnife® and TomoTherapy® Systems continue
to set the standard for overall user satisfaction. The
Accuray systems received the highest composite overall user
satisfaction rating among radiation treatment delivery systems in
the U.S., according to the Q2 2016 MD Buyline Market Intelligence
Briefing™. The most recent ratings trend also shows Accuray has
achieved the highest ratings among industry peers over the past
three years.
In rating the Accuray systems, MD Buyline reports the company
obtained the highest scores in a majority of categories measured
including system performance, system reliability, service response
time and service repair quality. CyberKnife System users also
"highly recommend" the InCise™ Multileaf Collimator (MLC) noting
"it makes the treatment time much more efficient." CyberKnife
and TomoTherapy System users continued to "praise the high level of
reliability afforded by Accuray systems."
"The independent MD Buyline report is further evidence we are
succeeding with our strategy to drive innovative cancer care with a
clear focus on customer satisfaction," said Joshua H. Levine, president and CEO of Accuray.
"The feedback continues to validate the TomoTherapy System's
functionality as a workhorse radiation oncology device while also
highlighting the expanded efficiency of our next generation
CyberKnife System equipped with an MLC. Our strong overall
user satisfaction ratings are a major factor behind our growth in
the marketplace."
For more information on the CyberKnife and TomoTherapy Systems
visit www.accuray.com.
MD Buyline, an independent market intelligence organization for
the healthcare industry, measures linear accelerator user
satisfaction based on evaluations by more than 3,300 hospitals in
its member network that use the product every day. Respondents rate
how satisfied they are with products from Accuray, Elekta and
Varian, using key metrics listed above along with installation and
implementation, applications training, and service repair quality.
(MD Buyline User Satisfaction Ratings, MD Buyline Market
Intelligence Briefing™ Q2 2016) © 2016 MD Buyline, All Rights
Reserved. Used with Permission July 13,
2016.
About the CyberKnife and TomoTherapy Systems
The Accuray CyberKnife M6™ Series and TomoTherapy H™ Series
treatment solutions cover the entire spectrum of radiation therapy
needs. The CyberKnife M6 Series enables precise, high-quality,
high-dose distributions to be confidently delivered to the patient
with extreme accuracy over a minimum number of treatments, reducing
side effects and preserving patients' quality of life. The
CyberKnife System is the only robotic full-body radiosurgery system
available today. The TomoTherapy H Series efficiently enables
physicians to customize treatment plans for the entire range of
radiation therapy patients and disease types. Its innovative design
enables treatment plans to be delivered with integrated, daily CT
image guidance, enhancing accuracy and delivering highly precise,
intensity-modulated radiation for optimal sparing of healthy tissue
and critical structures.
About Accuray
Accuray Incorporated (NASDAQ: ARAY) is a radiation oncology company
that develops, manufactures and sells precise, innovative tumor
treatment solutions that set the standard of care with the aim of
helping patients live longer, better lives. The company's
leading-edge technologies deliver the full range of radiation
therapy and radiosurgery treatments. For more information, please
visit www.accuray.com.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to future growth, market
success, adoption of our new products and services, benefits of our
technologies, and Accuray's leadership position in radiation
oncology innovation and technologies. Forward-looking statements
are subject to risks and uncertainties that could cause actual
results to differ materially from expectations, including but not
limited to the risks detailed from time to time under the heading
"Risk Factors" in the company's report on Form 10-K, filed on
August 28, 2015, the company's
reports on Form 10-Q, filed on November 5,
2015, February 1, 2016 and
April 29, 2016, and the company's
other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to
Accuray at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
Media
Contacts:
|
Investor
Contact:
|
Beth
Kaplan
|
Doug Sherk
|
Accuray
|
Investor Relations,
EVC Group
|
+1 (408)
789-4426
|
+1 (415)
652-9100
|
bkaplan@accuray.com
|
dsherk@evcgroup.com
|
|
|
Danielle
Sullivan
|
|
MSLGROUP
|
|
+1 (781)
684-6680
|
|
Danielle.sullivan@mslgroup.com
|
|
Logo - http://photos.prnewswire.com/prnh/20160108/320376LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/accuray-products-continue-to-receive-highest-composite-user-satisfaction-ratings-in-latest-md-buyline-report-300298614.html
SOURCE Accuray Incorporated